BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 23615841)

  • 41. Design and evaluation of a multi-epitope DNA vaccine against HPV16.
    Zhu L; Cui X; Yan Z; Tao Y; Shi L; Zhang X; Yao Y; Shi L
    Hum Vaccin Immunother; 2024 Dec; 20(1):2352908. PubMed ID: 38780076
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intravaginal HPV DNA vaccination with electroporation induces local CD8+ T-cell immune responses and antitumor effects against cervicovaginal tumors.
    Sun Y; Peng S; Qiu J; Miao J; Yang B; Jeang J; Hung CF; Wu TC
    Gene Ther; 2015 Jul; 22(7):528-35. PubMed ID: 25786869
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Enhancement of therapeutic DNA vaccine potency by melatonin through inhibiting VEGF expression and induction of antitumor immunity mediated by CD8+ T cells.
    Baghban Rahimi S; Mohebbi A; Vakilzadeh G; Biglari P; Razeghi Jahromi S; Mohebi SR; Shirian S; Gorji A; Ghaemi A
    Arch Virol; 2018 Mar; 163(3):587-597. PubMed ID: 29149434
    [TBL] [Abstract][Full Text] [Related]  

  • 44. HPV16 E5 peptide vaccine in treatment of cervical cancer in vitro and in vivo.
    Liao SJ; Deng DR; Zeng D; Zhang L; Hu XJ; Zhang WN; Li L; Jiang XF; Wang CY; Zhou JF; Wang SX; Zhang HW; Ma D
    J Huazhong Univ Sci Technolog Med Sci; 2013 Oct; 33(5):735-742. PubMed ID: 24142729
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-lasting immunoprotective and therapeutic effects of a hyperstable E7 oligomer based vaccine in a murine human papillomavirus tumor model.
    Cerutti ML; Alonso LG; Tatti S; de Prat-Gay G
    Int J Cancer; 2012 Apr; 130(8):1813-20. PubMed ID: 21780110
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunological responses and anti-tumor effects of HPV16/18 L1-L2-E7 multiepitope fusion construct along with curcumin and nanocurcumin in C57BL/6 mouse model.
    Kayyal M; Bolhassani A; Noormohammadi Z; Sadeghizadeh M
    Life Sci; 2021 Nov; 285():119945. PubMed ID: 34516991
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Therapeutic immunization and local low-dose tumor irradiation, a reinforcing combination.
    Draghiciu O; Walczak M; Hoogeboom BN; Franken KL; Melief KJ; Nijman HW; Daemen T
    Int J Cancer; 2014 Feb; 134(4):859-72. PubMed ID: 23922012
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A novel recombinant protein vaccine containing the different E7 proteins of the HPV16, 18, 6, 11 E7 linked to the HIV-1 Tat (47-57) improve cytotoxic immune responses.
    Mousavi T; Valadan R; Rafiei A; Abbasi A; Haghshenas MR
    Biotechnol Lett; 2021 Sep; 43(9):1933-1944. PubMed ID: 34313864
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chimeric infectious bursal disease virus-like particles as potent vaccines for eradication of established HPV-16 E7-dependent tumors.
    Martin Caballero J; Garzón A; González-Cintado L; Kowalczyk W; Jimenez Torres I; Calderita G; Rodriguez M; Gondar V; Bernal JJ; Ardavín C; Andreu D; Zürcher T; von Kobbe C
    PLoS One; 2012; 7(12):e52976. PubMed ID: 23300838
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression.
    Rice AE; Latchman YE; Balint JP; Lee JH; Gabitzsch ES; Jones FR
    Cancer Gene Ther; 2015 Sep; 22(9):454-62. PubMed ID: 26337747
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immune responses and therapeutic antitumor effects of an experimental DNA vaccine encoding human papillomavirus type 16 oncoproteins genetically fused to herpesvirus glycoprotein D.
    Diniz MO; Lasaro MO; Ertl HC; Ferreira LC
    Clin Vaccine Immunol; 2010 Oct; 17(10):1576-83. PubMed ID: 20739505
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6.
    Peng S; Ji H; Trimble C; He L; Tsai YC; Yeatermeyer J; Boyd DA; Hung CF; Wu TC
    J Virol; 2004 Aug; 78(16):8468-76. PubMed ID: 15280455
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Control of Spontaneous HPV16 E6/E7 Expressing Oral Cancer in HLA-A2 (AAD) Transgenic Mice with Therapeutic HPV DNA Vaccine.
    Tseng SH; Liu L; Peng S; Kim J; Ferrall L; Hung CF; Wu T-
    J Biomed Sci; 2021 Sep; 28(1):63. PubMed ID: 34517865
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Genetically modified cellular vaccines for therapy of human papilloma virus type 16 (HPV 16)-associated tumours.
    Bubenik J
    Curr Cancer Drug Targets; 2008 May; 8(3):180-6. PubMed ID: 18473731
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prevention and treatment of HPV-related cancer through a mRNA vaccine expressing APC-targeting antigen.
    Li X; Wang H; Lai W; Liao J; Mo W; Huang K; He L; Liang X; Yu Z; Xu J; Hua X; Hou F; Ding J; Jia WW; Zhang K; Wang Y
    Immunology; 2024 Jul; 172(3):375-391. PubMed ID: 38471664
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Enhanced Cytotoxic CD8 T Cell Priming Using Dendritic Cell-Expressing Human Papillomavirus-16 E6/E7-p16INK4 Fusion Protein with Sequenced Anti-Programmed Death-1.
    Garcia-Bates TM; Kim E; Concha-Benavente F; Trivedi S; Mailliard RB; Gambotto A; Ferris RL
    J Immunol; 2016 Mar; 196(6):2870-8. PubMed ID: 26851223
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Coadministration of the fungal immunomodulatory protein FIP-Fve and a tumour-associated antigen enhanced antitumour immunity.
    Ding Y; Seow SV; Huang CH; Liew LM; Lim YC; Kuo IC; Chua KY
    Immunology; 2009 Sep; 128(1 Suppl):e881-94. PubMed ID: 19740349
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Polymeric nanoparticles for co-delivery of synthetic long peptide antigen and poly IC as therapeutic cancer vaccine formulation.
    Rahimian S; Fransen MF; Kleinovink JW; Christensen JR; Amidi M; Hennink WE; Ossendorp F
    J Control Release; 2015 Apr; 203():16-22. PubMed ID: 25660830
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combination Vaccination With Tetanus Toxoid and Enhanced Tumor-Cell Based Vaccine Against Cervical Cancer in a Mouse Model.
    Alson D; Schuyler SC; Yan BX; Samimuthu K; Qiu JT
    Front Immunol; 2020; 11():927. PubMed ID: 32547541
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin.
    Hsieh CJ; Kim TW; Hung CF; Juang J; Moniz M; Boyd DA; He L; Chen PJ; Chen CH; Wu TC
    Vaccine; 2004 Sep; 22(29-30):3993-4001. PubMed ID: 15364449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.